RT Journal Article
SR Electronic
T1 Longitudinal gut microbial signals are associated with weight loss: insights from a digital therapeutics program
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.04.22284035
DO 10.1101/2023.01.04.22284035
A1 Kumbhare, Shreyas V.
A1 Pedroso, Inti
A1 Joshi, Bharat
A1 Muthukumar, Karthik M.
A1 Saravanan, Santosh K.
A1 Irudayanathan, Carmel
A1 Kochhar, Gursimran S.
A1 Dulai, Parambir S.
A1 Sinha, Ranjan
A1 Almonacid, Daniel E.
YR 2023
UL http://medrxiv.org/content/early/2023/01/11/2023.01.04.22284035.abstract
AB Obesity is a significant health problem due to its profound health deteriorating effects and high costs for healthcare systems. There exist lifestyle and pharmacological interventions available to prevent and reverse obesity; however, at the population level, these have shown to be insufficient, and we continue to see a worldwide increase in obesity prevalence. The gut microbiome has been shown to influence the susceptibility to weight gain and difficulty in losing weight and to be associated with successful long-term weight loss. Therefore, multiple studies have suggested that obesity interventions should consider the gut microbiome as a primary target through an improved diet and a crucial endpoint to monitor. However, there is a paucity of evidence regarding how to tailor the diet for an individual’s microbiome and what changes are expected to occur due to successful weight management. Digital therapeutics solutions have emerged as an exciting alternative to increase population access, reduce costs, and have the potential to accompany individuals on their health-promoting journey closely. Digbi Health has developed a dietary and lifestyle program to achieve weight loss that effectively reduces weight and improves diverse health outcomes by prioritizing and personalizing food ingredients to match an individual’s genetic profile and nurture the gut microbiome. In this study, we analyze the weight loss pattern and microbiome profile of 103 individuals to identify the effects of the weight loss program on the gut microbiome between their baseline and follow-up samples. We found that 80% of individuals lost weight during the study.Analysis of their gut microbiome identified genera, functional pathways, and microbial communities associated with BMI changes and dietary and lifestyle program. The microbial genera and functional pathways associated with a reduction in BMI during the study include several previously reported in the literature, including Akkermansia, Christensenella, Oscillospiraceae, Alistipes, and Sutterella, short-chain fatty acid (SCFA) production and degradation of simple sugars like arabinose, sucrose, and melibiose. Network analysis identified two microbiome communities associated with BMI, one of which also significantly responded to the weight loss program, which includes multiple known associations with BMI and obesity. Our findings provide additional evidence for using the gut microbiome as an endpoint of weight loss program and highlight how it positively impacts the gut microbiome, with significant parallels in weight loss and health outcomes. These results provide additional evidence for known microbiome biomarkers of obesity and highlight new ones that warrant further research.Competing Interest StatementThe digital therapeutics program provided to study participants in this work is a commercially available program developed and marketed by Digbi Health. All authors, except for P.D. and G.K. were employees or contractors of Digbi Health and may hold stocks or stock options on Digbi Health. G.K. was an advisor to Digbi Health and has received stock options from Digbi Health. P.D. has received consulting and/or research support from Takeda, Pfizer, Janssen, BMS, Gilead, Novartis, Lily; and royalties from PreciDiag. R.S. was CEO and founder of Digbi Health. D.A. has received royalties from Kura Biotech. S.K., I.P., R.S., and D.A. had patents pending concerning this work: US Application No. 17/817,558, Methods and systems for multi-omic interventions, and US Application No. 63/476,672, Methods and systems for longitudinal gut microbiome interventions as diagnostics for personalized care. The former conflicts of interest do not alter our adherence to policies on sharing data and materials.Funding StatementThis study was funded by Digbi Health, Mountain View, CA, United States. There were no additional funding sources.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of E&I Review Services (protocol code #18053 on 05/22/2018).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe microbiome sequence data used in this study were submitted to NCBI SRA under Bioproject accession number PRJNA907500. https://www.ncbi.nlm.nih.gov/bioproject/PRJNA907500